Evidence map›Paper›PMID 35005115›Full record

ArticleGenes & diseases2022

LPCAT1 functions as a novel prognostic molecular marker in hepatocellular carcinoma.

Hongbin Zhang, Ke Xu, Qin Xiang, Lijuan Zhao, Benxu Tan, Ping Ju, Xiufu Lan, Yi Liu, Jian Zhang, Zheng Fu and 8 more

Open access · diamondAbstract read
In one paragraph

Article in Genes & diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 2 countries.

Hongbin ZhangDepartment of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong 250117, PR China.
Ke XuChongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, PR China.
Qin XiangChongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, PR China.
Lijuan ZhaoDepartment of Oncology, Yongchuan Hospital of Chongqing Medical University, Chongqing 402177, PR China.
Benxu TanDepartment of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, PR China.
Ping JuCollege of Science and Mathematics, West Chester University of Pennsylvania, West Chester, PA 19383, USA.
Xiufu LanDepartment of Orthopedics, Daping Hospital, Army Medical University, Chongqing 400042, PR China.
Yi LiuEngineering Department, Women & Children's Health Care Hospital of Linyi, Linyi, Shandong 276016, PR China.
Jian ZhangDepartment of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250013, PR China.
Zheng FuDepartment of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong 250013, PR China.
Chao LiDepartment of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong 250117, PR China.
Jinzhi WangDepartment of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong 250117, PR China.
Jixiang SongMedical Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong 250013, PR China.
Yun XiaoDepartment of Oncology, Chongqing Traditional Chinese Medicine Hospital, Chongqing 400042, PR China.
Zhaobo ChengChongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, PR China.
Yan WangChongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, PR China.
Shu ZhangDepartment of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong 250117, PR China.
Tingxiu XiangChongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, PR China.
Shandong Tumor Hospital · CNThe Affiliated Yongchuan Hospital of Chongqing Medical University · CNArmy Medical University · CNChongqing Medical University · CNFirst Affiliated Hospital of Chengdu Medical College · CNFirst People's Hospital of Chongqing · CNJinan Central Hospital · CNLinyi People's Hospital · CNPeople’s Hospital of Rizhao · CNWest Chester University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to investigate the relationships between LPCAT1 expression and clinicopathologic parameters of hepatocellular carcinoma (HCC), further, to explore the effect of LPCAT1 on overall survival (OS) in patients with HCC, and its possible mechanism. Bioinformatics analysis using high throughput RNA-sequencing data from TCGA was utilized to explore the differential expression of LPCAT1 between normal and tumor tissues, and the associations between LPCAT1 expression and clinicopathological parameters. Survival analyses and subgroup survival analyses were utilized to elucidate the effect of LPCAT1 on OS in patients with HCC. Univariate analysis and multivariate analysis were used to investigate the prognostic factors. Potential LPCAT1 related tumor genes were identified by the methodology of differentially expressed genes (DEGs) screening. GO term enrichment analysis, KEGG pathway analysis and the PPI network were used to explore the potential mechanism. LPCAT1 was significantly overexpressed in HCC tumor tissues compared with normal tissues. The LPCAT1 expression was related to tumor grade, ECOG score, AFP and TNM stage, with

Indexed as

CDK1HCCLPCAT1Overall survivalPrognostic marker

Identifiers

PMID35005115
PMCPMC8720658
OpenAlexW3044599479

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.